Fortress Biotech (FBIO) Announces Quarterly Earnings Results

Fortress Biotech (NASDAQ:FBIO) released its earnings results on Friday. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.18, MarketWatch Earnings reports. Fortress Biotech had a negative net margin of 47.97% and a negative return on equity of 71.96%. The firm had revenue of $63.69 million for the quarter, compared to analyst estimates of $64.88 million.

FBIO stock traded up $0.01 during mid-day trading on Friday, hitting $1.10. The stock had a trading volume of 194,583 shares, compared to its average volume of 336,941. The company has a quick ratio of 2.76, a current ratio of 2.76 and a debt-to-equity ratio of 0.76. Fortress Biotech has a 52 week low of $0.83 and a 52 week high of $5.54. The firm has a market cap of $59.23 million, a P/E ratio of -0.68 and a beta of 1.46.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a report on Friday, August 10th. HC Wainwright set a $11.00 target price on shares of Fortress Biotech and gave the company a “buy” rating in a report on Friday, August 10th. Finally, ValuEngine lowered shares of Fortress Biotech from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $10.67.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at

About Fortress Biotech

Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Earnings History for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with's FREE daily email newsletter.

Leave a Reply